Browse > Article

Factors Affecting $^{18}F$-Fluorodeoxyglucose (FDG) Uptake in Breast Cancer  

Jeong, Sun-Hye (Department of Radiology, Soonchunhyang University Bucheon Hospital)
Lee, Eun-Hye (Department of Radiology, Soonchunhyang University Bucheon Hospital)
Park, Jung-Mi (Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital)
Lee, Hae-Kyung (Department of Radiology, Soonchunhyang University Bucheon Hospital)
Yi, Boem-Ha (Department of Radiology, Soonchunhyang University Bucheon Hospital)
Choi, Na-Mi (Department of Radiology, Konkuk University Hospital)
Publication Information
Journal of the Korean Society of Radiology / v.63, no.3, 2010 , pp. 287-292 More about this Journal
Abstract
Purpose: To evaluate factors affecting $^{18}F$-Fluorodeoxyglucose (FDG) uptake in breast cancer. Materials and Methods: For 3 years from 2006, 180 patients (mean age 48-years-old) with 187 breast cancers underwent positron emission tomography-computed tomography (PET/CT; biograph2, Siemens) at our institute and were enrolled in this study. We evaluated whether there was a correlation between the peak standardized uptake value (pSUV) of PET/CT and the histologic type of the breast cancers (n=187), grade of the invasive ductal cancers (n=142), and tumor size (n=153). Results: The different histologic types of breast cancers include IDCs (n=156), in situ ductal carcinoma (n=10), papillary cancer (n=6), mucinous cancer (n=6), invasive lobular cancer (n=4), medullary cancer (n=3), metaplastic cancer (n=1), and neuroendocrine cancer (n=1). pSUV showed significant differences according to histologic type (p<0.005). For the available cases (n=142), IDCs were classified as grade 1 (n=25), grade 2 (n=66), and grade 3 (n=51) and correlated with the histologic grade of IDCs (rho=0.41, p<0.001). pSUV was correlated with tumor size regardless of histologic type (rho=0.525, p<0.001). In low grade IDCs, pSUV was correlated with tumor size (rho=0.48-0.86, p<0.001), but not in high grade IDCs (p>0.001). Conclusion: Regardless of histologic type, the larger the breast cancer, the higher the pSUV; in addition, the higher the grade of IDCs, the higher the pSUV. For the low grade IDCs, pSUV is correlated with tumor size; however, this is not the case in high grade IDCs.
Keywords
Breast Neoplasms; Positron-Emission Tomography; Fluorodeoxyglucose F18;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18: 3495-3502
2 Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad Radiol 2002;9:773-783   DOI   ScienceOn
3 Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2- fluoro-D-glucose PET. Radiology 1993;187:743-750
4 Buck A, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S80-S87   DOI
5 Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29:1317-1323   DOI   ScienceOn
6 Palmedo H, Bender H, Grunwald F, Mallmann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99 m methoxyisobuty lisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997;24:1138-1145
7 Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267-274   DOI   ScienceOn
8 유정현, 최혜영, 안세현. 유방X-선 촬영술에서 오진한 유방암의 후향적 연구. 대한방사선의학회지 1995;32:501-506
9 박현주, 한 현, 임달모, 정효선, 김지은, 김영채. 유방암의 X-선유방 촬영술 소견의 분석. 대한방사선의학회지 1995;32:337-342
10 Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998; 39:431-435
11 오기근, 문우경, 손은주, 김미혜, 정수영, 고경란 등. 유방질환의 영상검사. In 정수영, 한부경, 대한유방영상의학회. 유방영상진단학. 일조각. 2008:121
12 Lim HS, Yoon W, Chung TW, Kim JK, Park JG, Kang HK, et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007;27:S197-S213   DOI   ScienceOn
13 Noh DY, Yun IJ, Kim JS, Kang HS, Lee DS, Chung JK, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg 1998;22:223-228   DOI   ScienceOn
14 Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770   DOI
15 Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [$^{18}F$]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-1434   DOI
16 Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, et al. Glucose metabolism of breast cancer assessed by $^{18}F$-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16
17 Crowe JP, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994;1:132-140   DOI   ScienceOn
18 Kumar R, Alavi A. Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 2004;42:1113-1122   DOI   ScienceOn
19 Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005;35:84-99   DOI   ScienceOn
20 Rosen EL, Eubank WB, Mankoff DA, FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27:S215-S229   DOI   ScienceOn
21 Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussel K, et al. Fluorine-182-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001;28:351-358   DOI